CY1108843T1 - 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων - Google Patents

3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων

Info

Publication number
CY1108843T1
CY1108843T1 CY20091100221T CY091100221T CY1108843T1 CY 1108843 T1 CY1108843 T1 CY 1108843T1 CY 20091100221 T CY20091100221 T CY 20091100221T CY 091100221 T CY091100221 T CY 091100221T CY 1108843 T1 CY1108843 T1 CY 1108843T1
Authority
CY
Cyprus
Prior art keywords
schizophrenia
cis
treatment
dimrodetretravenasine
psychologies
Prior art date
Application number
CY20091100221T
Other languages
Greek (el)
English (en)
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Original Assignee
Biovail Laboratories International (Barbados) Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Biovail Laboratories International (Barbados) Srl filed Critical Biovail Laboratories International (Barbados) Srl
Publication of CY1108843T1 publication Critical patent/CY1108843T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20091100221T 2005-08-06 2009-02-26 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων CY1108843T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds
EP06765238A EP1855677B1 (en) 2005-08-06 2006-08-04 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Publications (1)

Publication Number Publication Date
CY1108843T1 true CY1108843T1 (el) 2014-07-02

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100221T CY1108843T1 (el) 2005-08-06 2009-02-26 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων

Country Status (20)

Country Link
US (1) US20110257220A1 (enExample)
EP (2) EP1855677B1 (enExample)
JP (1) JP2009504622A (enExample)
KR (1) KR20080033500A (enExample)
AT (2) ATE534391T1 (enExample)
AU (1) AU2006277753B2 (enExample)
CA (1) CA2620960A1 (enExample)
CY (1) CY1108843T1 (enExample)
DE (1) DE602006004009D1 (enExample)
DK (1) DK1855677T3 (enExample)
ES (1) ES2318771T3 (enExample)
HR (1) HRP20090074T3 (enExample)
MX (1) MX2008001549A (enExample)
NZ (1) NZ566011A (enExample)
PL (1) PL1855677T3 (enExample)
PT (1) PT1855677E (enExample)
RS (1) RS50807B (enExample)
RU (1) RU2407743C2 (enExample)
SI (1) SI1855677T1 (enExample)
WO (1) WO2007017654A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
JP2013527237A (ja) 2010-06-01 2013-06-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド ベンゾキノロン系vmat2阻害剤
US9658363B2 (en) 2011-04-01 2017-05-23 3M Innovative Properties Company Films including triazine-based ultraviolet absorbers
EP3099299A4 (en) 2014-01-27 2017-10-04 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US9782398B2 (en) * 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
US10065952B2 (en) 2015-10-30 2018-09-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
EP3548027A1 (en) * 2016-12-02 2019-10-09 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
EA202090676A1 (ru) 2017-01-27 2021-10-08 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
IL273300B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
CA2058640A1 (en) * 1991-01-25 1992-07-26 Richard R. Scherschlicht Tricyclic pyridone derivative
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
RU2407743C2 (ru) 2010-12-27
SI1855677T1 (sl) 2009-04-30
ATE534391T1 (de) 2011-12-15
AU2006277753A1 (en) 2007-02-15
KR20080033500A (ko) 2008-04-16
DE602006004009D1 (de) 2009-01-15
JP2009504622A (ja) 2009-02-05
HK1111083A1 (en) 2008-08-01
US20110257220A1 (en) 2011-10-20
PT1855677E (pt) 2009-01-13
EP1855677B1 (en) 2008-12-03
ATE415968T1 (de) 2008-12-15
DK1855677T3 (da) 2009-02-09
CA2620960A1 (en) 2007-02-15
EP2050451A1 (en) 2009-04-22
WO2007017654A1 (en) 2007-02-15
RU2008108623A (ru) 2009-09-20
PL1855677T3 (pl) 2009-07-31
EP1855677A1 (en) 2007-11-21
RS50807B (sr) 2010-08-31
AU2006277753B2 (en) 2011-11-10
HRP20090074T3 (en) 2009-04-30
NZ566011A (en) 2011-01-28
MX2008001549A (es) 2008-04-04
ES2318771T3 (es) 2009-05-01
EP2050451B1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
TW200801006A (en) Fused bicyclic mTOR inhibitors
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1115426T1 (el) 1,3-δισυποκατεστημενα παραγωγα ιμιδαζολιδιν-2-ονης ως αναστολεις toy cyp 17
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1113108T1 (el) Μεσυλικο προφαρμακου λεβοντοπα, συνθεσεις αυτου, και χρησεις αυτου
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
MX2008001546A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de una enfermedad proliferativa o una inflamacion.
EA200870584A1 (ru) Пролекарства пенема
MX2010001303A (es) Compuestos terapeuticos.
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
MX2010001304A (es) Compuestos terapeuticos.
TW200621260A (en) Selected fused heterocyclics and uses thereof
DK1713438T3 (da) Medicinsk sæbe
CY1108865T1 (el) Υποκατεστημενες 2,5-διαμινομευθυλο-1η-πυρρολες